11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 10.10.2026 Expectation: 2500 pips
Buy AUDCAD upon breaking 1.00000
Yesterday at 09:31 AM 16
Period: 24.10.2026 Expectation: 8500 pips
Invest in ETHUSD with $2,565 target
Yesterday at 08:17 AM 21
Period: 23.09.2026 Expectation: 2500 pips
NVIDIA sell-off targets $200
09 September 2026 37
Period: 31.12.2026 Expectation: 16000 pips
Sell EURUSD in medium term
09 September 2026 24
Period: 23.09.2026 Expectation: 2200 pips
Go long on EURUSD ahead of ECB meeting
09 September 2026 22
Period: 08.10.2026 Expectation: 100 pips
Buying SPX with $7,815 target
08 September 2026 35
Go to forecasts